|
Zinc Finger Recombinases for Endogenous Genome Tailoring
|
1R21CA126664-01A2
|
$209,700
|
BARBAS, CARLOS
|
SCRIPPS RESEARCH INSTITUTE
|
|
Yale SPORE in Skin Cancer
|
5P50CA121974-03
|
$2,233,298
|
HALABAN, RUTH
|
YALE UNIVERSITY
|
|
X-ray Targeted Therapeutic Genes within Nanoparticles
|
5R01CA125757-02
|
$362,375
|
Hallahan, Dennis
|
VANDERBILT UNIVERSITY
|
|
Virotherapy for Relapsed Refractory Multiple Myeloma
|
5R01CA125614-03
|
|
DISPENZIERI, ANGELA
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
|
Viral Proteins: Gene Delivery to Specific Malignancies
|
5R01CA081171-08
|
$249,183
|
ALBRITTON, LORRAINE
|
UNIVERSITY OF TENNESSEE HEALTH SCI CTR
|
|
VEGFs in Artery-Vein Imbalance in AIDS-Kaposi Sarcoma
|
5R01CA079218-09
|
$328,425
|
Gill, Parkash
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
VCU Minority-Based CCOP
|
5U10CA052784-18
|
$577,110
|
ROBERTS, JOHN
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
Vasculogenesis in Ewing's Sarcoma: Implications for Therapy
|
2R01CA103986-04A1
|
$254,023
|
Kleinerman, Eugenie
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Validation of a New Target for Prostate Cancer Therapy
|
5R01CA102688-05
|
$289,700
|
BARON, VERONIQUE
|
SIDNEY KIMMEL CANCER CENTER
|
|
UTMDACC SPORE in Breast Cancer
|
5P50CA116199-04
|
$2,180,817
|
HORTOBAGYI, GABRIEL
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
USING VIRAL NANOPARTICLES TO TARGET CANCER
|
5R01CA112075-04
|
$746,719
|
MANCHESTER, MARIANNE
|
SCRIPPS RESEARCH INSTITUTE
|
|
Unusual Regulation of the NF-kappaB/IKK Pathway by Ras
|
5R01CA073756-10
|
$249,182
|
BALDWIN JR, ALBERT
|
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
|
|
University of Texas SPORE in Lung Cancer
|
2P50CA070907-11
|
$2,300,000
|
MINNA, JOHN
|
UNIVERSITY OF TEXAS SW MED CTR/DALLAS
|
|
University of Texas MD Anderson SPORE in Ovarian Cancer
|
5P50CA083639-09
|
$2,180,816
|
BAST, ROBERT
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
University of Texas M.D. Anderson Cancer Center SPORE - Leukemia
|
2P50CA100632-06
|
$2,300,000
|
ISSA, JEAN-PIERRE
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
University of Texas M.D. Anderson Cancer Center SPORE - Leukemia
|
3P50CA100632-06S1
|
$40,163
|
ISSA, JEAN-PIERRE
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Ultraviolet-Induced Signal Trasduction
|
5R01CA077646-09
|
$236,453
|
DONG, ZIGANG
|
UNIVERSITY OF MINNESOTA TWIN CITIES
|
|
UCB-DERIVED CD19-SPECIFIC T CELLS FOR UNIVERSAL TREATMENT OF B-CELL MALIGNANCY
|
5R21CA116127-02
|
$168,750
|
COOPER, LAURENCE
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Ubiquitin-Proteolytic Control of HOXA9 in Leukemogenesis
|
5R01CA118085-03
|
$290,571
|
ZHOU, PENGBO
|
WEILL MEDICAL COLLEGE OF CORNELL UNIV
|
|
Tumor-Targeting Oligonucleotides
|
5R01CA122383-03
|
$255,082
|
BATES, PAULA
|
UNIVERSITY OF LOUISVILLE
|
|
Tumor-targeted silencing of Bcl-2/Bcl-xL by the self-assembled siRNA-nanovectors
|
5R01CA121830-03
|
$258,587
|
Xu, Liang
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
Tumor targeted RNAi by novel nanovectors for molecular therapy of prostate cancer
|
5R21CA128220-02
|
$127,680
|
Xu, Liang
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
Tumor Sensitization to Purine Analogs by E. coli PNP
|
5R01CA119170-03
|
$332,765
|
SORSCHER, Eric
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Tumor Immunology Institutional Training Grant
|
5T32CA009120-33
|
$209,005
|
Dubinett, Steven
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Tumor Hypoxia Imaging - Laboratory and Clinical Studies
|
5P01CA115675-03
|
$1,863,192
|
LING, CLIFTON
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
|
Tumor and PTK-Targeted Therapy by FUS1 and PTK inhibitor
|
5R01CA116322-02
|
$292,600
|
JI, LIN
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Treatment of Malignant Gliomas with 2-5A-anti-hTR
|
5R01CA108558-05
|
$293,510
|
BOGLER, OLIVER
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Transposon Mediated Gene Therapy for Colorectal Cancer
|
5R01CA120383-02
|
$290,033
|
McIvor, R
|
UNIVERSITY OF MINNESOTA TWIN CITIES
|
|
Translational Breast Cancer Research Training Program
|
2T32CA090221-06A1
|
$270,534
|
FUQUA, SUZANNE
|
BAYLOR COLLEGE OF MEDICINE
|
|
Translational Applications of mda-7/IL-24 in Cancer
|
7P01CA104177-04
|
$1,329,682
|
FISHER, PAUL
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
Transgenic in vivo delivery of MDA7/IL24 for maligannt glioma therapy
|
1R01CA129489-01A2
|
$342,194
|
GERMANO, ISABELLE
|
MOUNT SINAI SCHOOL OF MEDICINE OF NYU
|
|
Transformation of Cells by the REL Oncogene
|
3R01CA047763-20S1
|
$10,000
|
GILMORE, THOMAS
|
BOSTON UNIVERSITY
|
|
Transformation of Cells by the REL Oncogene
|
5R01CA047763-21
|
$275,637
|
GILMORE, THOMAS
|
BOSTON UNIVERSITY
|
|
Transduction of T-cells to improve migration to tumor
|
5R01CA116206-04
|
$282,772
|
HWU, PATRICK
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Training Program in Molecular Oncology and Immunology
|
5T32CA009161-34
|
$556,042
|
PELLICER, ANGEL
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
Training Program in Free Radical and Radiation Biology
|
5T32CA078586-09
|
$224,027
|
Spitz, Douglas
|
UNIVERSITY OF IOWA
|
|
TRAINING IN CANCER BIOLOGY AND TRANSPLANTATION
|
5T32CA009515-24
|
$683,939
|
APPELBAUM, FREDERICK
|
UNIVERSITY OF WASHINGTON
|
|
TRAINING GRANT IN VIRAL AND CHEMICAL CARCINOGENESIS
|
2T32CA009320-24
|
$241,247
|
JONES, PETER
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
Training Grant in Cancer Biology
|
2T32CA009126-31A1
|
$395,031
|
MAY, W
|
UNIVERSITY OF FLORIDA
|
|
TRAIL-induced apoptosis in prostate cancer
|
5R01CA102218-05
|
$249,182
|
VOELKEL-JOHNSON, CHRISTINA
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
|
Toward a transcription therapy for breast cancer
|
5R01CA113682-03
|
$268,871
|
MUYAN, MESUT
|
UNIVERSITY OF ROCHESTER
|
|
Tissue Specific Gene Therapy for Human Prostate Cancer
|
5R01CA074042-11
|
$265,033
|
Kao, Chinghai
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
Therapeutic VEGFR-2 Silencing via Targeted Nanoparticles
|
1F32CA132546-01A2
|
$51,278
|
Greene, Rachel
|
VANDERBILT UNIVERSITY
|
|
Therapeutic Potential of IL-15 Plasmid Delivery to Tumors Using Electroporation
|
1R01CA122518-01A2
|
$333,775
|
HELLER, RICHARD
|
UNIVERSITY OF SOUTH FLORIDA
|
|
The UCLA Center for In Vivo Imaging in Cancer Biology
|
5P50CA086306-09
|
$1,890,657
|
HERSCHMAN, HARVEY
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
THE THERAPY OF AML
|
5P01CA055164-16
|
$2,374,635
|
ANDREEFF, MICHAEL
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
The Small DNA Tumor Virus Conference
|
5R13CA083239-10
|
$7,000
|
LAMBERT, PAUL
|
UNIVERSITY OF WISCONSIN MADISON
|
|
The Roles of HBXAP Gene in Ovarian Cancer
|
1R01CA129080-01A1
|
$340,300
|
SHIH, IE-MING
|
JOHNS HOPKINS UNIVERSITY
|
|
The role of p53 in remodeling DNA methylation in cancer
|
5R01CA106630-05
|
$244,189
|
TAYLOR, SHIRLEY
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
The role of JNK in Mammary tumor development
|
5R01CA100238-06
|
$278,349
|
VAN DEN BERG, CARLA
|
UNIVERSITY OF TEXAS AUSTIN
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|